

Cumulative Index 1990

Volume 17

<i>March</i>	STIMULATION AND THE PRETERM INFANT , pages 1-244
<i>June</i>	NEONATAL JAUNDICE , pages 245-511
<i>September</i>	PART I: FETAL DYSMORPHOLOGY , pages 513-748
<i>December</i>	PART II: FETAL CLINICAL GENETICS , pages 749-956

Note: Page numbers for complete issues and article titles are in **boldface** type.

- Aase syndrome, 656
 Abdominal abnormalities, congenital, **675-702**
 abdominal and gastrointestinal defects, 680-682
 abdominal wall defects, 682-687
 gastroschisis, 685-687
 omphalocele, 682-685
 diaphragmatic hernias, 687-688
 duodenal atresia, 688-689
 embryology, 676-677
 intestinal atresias and stenosis, 689-690
 renal malformations, 690-698
 agenesis, 690-693
 cystic disorders, 693
 osathanondh, and Potter type I (infantile polycystic disease), 693
 and Potter type II (multicystic dysplasia), 694-695
 and Potter type III (adult polycystic disease), 696
 and Potter type IV, 696
 posterior urethral valves and prune belly syndrome, 697-698
 ultrasound in normal fetus, 677-680
 Abdominal wall, congenital defects, 682-687
 Abortion, dystrophin analysis, 857-858
 habitual, 752
 Acquired immunodeficiency syndrome (AIDS), and fetal anomalies, 563
 Acyl-CoA dehydrogenase deficiency, long chain, 766-767
 medium chain, 766
 multiple, 769-770
 Adrenal, autopsy findings in hyperbilirubinemia, 385
 Adult diseases, genetics of, **889-910**
 atherosclerosis, 891-897
 colon cancer, 897-900
 diabetes mellitus, 900-906
 Alagille syndrome, 650
 Alcohol, and fetal anomalies, 554-555
 Alpha-1,4-glucosidase deficiency, 771
 Amino acid metabolism, inborn errors of, 767-768
 Aminopterin, and fetal anomalies, 556
 Amniocentesis, 762
 for osteogenesis imperfecta, 803
 Amnion, early rupture sequence, 573-575
 Amniotic fluid, laboratory measurement of bilirubin, 410-412
 Anatomy, of cystic hygroma, posterior nuchal, 611-613
 in normal fetus, 923-926
 normal ultrasonography of fetal head and spine, 598-600
 of posterior urethral valves, 221-223
 Anencephaly, 578-580
 ultrasound imaging, 600-601
 Anesthesia, and neonatal stress responses, 212
 Animal studies, teratogenically-induced fetal anomalies, 549-550
 Anticonvulsants, and fetal anomalies, 556-559
 Antioxidants, bilirubin role, 362-364
 and heat-shock proteins, 361-362
 alpha-Antitrypsin deficiency, 488

- Apert syndrome, 650
 Aprosencephaly, 576-577
 Argininosuccinic aciduria, 768-769
 Arnold-Chiari malformations, 585-586
 Atelencephaly, 576-577
 Atherosclerosis, 891-897
 clinical approach and counseling, 896-897
 genetics, 893-896
 risk factors and lipids, 892-893
 Atresia, biliary, 485-486
 Auditory brainstem responses (ABR), 59-60
 Autopsy, fetal-neonatal cystic hygroma, posterior nuchal, 615
 in hyperbilirubinemia, 381-396
 adrenal, 385
 central nervous system, 385-386
 gross findings, 390
 heart, 383
 kernicterus history, 386-390
 kidney, 383
 late changes, 391-393
 liver, 382-383
 lung, 383-385
 microscopic findings, 391
 pancreas, 385
 in pregnancy loss, 737-738
- Baller-Gerold syndrome, 657
 Bardet-Biedl syndrome, 656
 Becker muscular dystrophy. *See Muscular dystrophies, Duchenne and Becker.*
 Beckwith-Wiedemann syndrome, 661
 Behavior of preterm infants, in newborn period. *See Preterm infants, behavior in newborn periods.*
 and psychophysiologic assessment, 155-172
 responsivity of, 113-123
 and intraventricular hemorrhage, 114-118
 prematurity and complications, effects of, 119-122
 Beta-ketothiolase deficiency, 766
 Bile ducts, interlobular, 487
 Bile, inspissated, 487-488
 Biliary disease. *See Cholestatic jaundice in newborn.*
 Bilirubin, as antioxidant, 362-364
 in brain. *See Brain bilirubin.*
 chemistry of, 451-452
 enterohepatic circulation, 260-261
 and heme oxygenase inhibitors, 261-264
 laboratory measurement. *See Laboratory measurement of bilirubin.*
 metabolism, and heme, 359-361
 neurotoxicity of, 308-309, 437-447
 kernicterus, 442-445
 toxicity to cells, 439-442
 NMR spectroscopy, 320-326
 non-albumin-bound, 452-453
 noninvasive measurements, 417-435
 measurement devices, 418-420
 transcutaneous bilirubinometry, 420-433
 as replacement for serum testing, 420-427
 as research tool, 432-433
 as screening device, 427-432
 pharmacologic effects, 249-252
 metabolic effects, 249-250
 disposition of, 250-252
 structure, 468-470
 Bilirubin encephalopathy, 371-379
 auditory abnormalities, 374
 bilirubin staining, 372
 chronic, after hyperbilirubinemia, 374-375
 clinical features, 373-374
 extrapyramidal disturbance, 374
 gaze abnormalities, 375
 without hyperbilirubinemia, 375-377
 intellectual deficits, 375
 neuronal injury, 373
 neuropathology, 371-372
 temporal evolution, 374
 Bilirubin oxidase, 405-406
 Binding of bilirubin, 156-459
 Biochemical screening, collagen defects in connective tissue diseases, 800-801
 Biopsy, fetal tissue, 763
 liver, in cholestatic jaundice, 499-500
 Blood flow, brain, and bilirubin deposition, 455
 Blood-brain barrier to bilirubin, 453-454
 Bone, in skeletal dysplasia, 704-706
 Bradycardia, and handling of preterm infants in hospitals, 106-109
 Brain, bilirubin, 449-465
 blood-brain barrier, 453-454
 brain blood flow, 455
 cellular binding, 456-459
 chemistry of bilirubin, 451-452
 entrance mechanisms, 459-461
 and hyperbilirubinemia, 450
 non-albumin-bound bilirubin, 452-453
 regional localization of, 455-456
 developing, differential functional plasticity, 62-63
 electrophysiology of function, 59
 hyperbilirubinemia effects, 331-358
 cognition, 332-339
 confounding and effect modification, 348-351
 hearing, 345-348
 limitations, implications, and conclusions, 354-356
 methods of study, 331-332
 neurologic abnormality, 339-345

- risk factor measurement, 351-354
 - plasticity, after damage, 67-74
 - mental and behavioral effects, 70-73
 - prevention of, 67-69
 - reduction of, 69-70
- structure and function, plasticity triggering experiences, 77-82
- Brainstem audiometric-evoked response, hyperbilirubinemia assessment, 294-298
- Brazelton neonatal behavioral assessment scale, in hyperbilirubinemia, 301-303
- Carbohydrate metabolism, and cholestasis, 491
 - inborn errors of, 770-771
- Cardiopulmonary bypass, inborn errors, 771-772
 - trace metal and vitamin metabolism, 771-772
 - Menke disease, 772
- Cardiovascular anatomy and function. See *Echocardiography, fetal*.
- Carpenter's syndrome, 656-657
- Carrier screening, sickle cell disease, 813-814
 - thalassemia, alpha-, 816-817
 - beta-, 820
- Cat-eye syndrome, heart defects, 649-650
- Central nervous system, abnormalities, 569-595
 - amion rupture, 573-575
 - Arnold-Chiari malformation, 585-586
 - atelencephaly/aprosencephaly, 576-577
 - corpus callosum agenesis, 573
 - craniosynostosis, 570-571
 - Dandy-Walker malformation, 586-588
 - deformation, 569-570
 - encephalocele, 581-583
 - gyral abnormalities, 571-572
 - heterotopias, 572
 - holoprosencephaly, 583-584
 - hydrocephalus, 584
 - neural tube defects, anencephaly, 578-580
 - myelomeningocele, 580-581
 - porencephaly and related defects, 575-576
 - autopsy findings in hyperbilirubinemia, 385-386
- Cerebellum, ultrasound imaging, 606
- Cerebral cortex, development and plasticity, 83-102
 - corticocortical connectivity, 91-98
 - retrograde tracings in prefrontal cortex, 92-94
 - termination of afferents and efferents, 94-98
 - in mature monkey, 84-91
 - afferent and efferent organization, 87-91
 - methods, 84-87
- Cerebrohepatorenal syndrome of Zellweger, 769
- CHARGE association, heart defects, 663
- CHILD syndrome, heart defects, 661
- Chimerism, 881-882
- Choledochal cyst, 486
- Cholestatic jaundice in newborn, 483-506
 - clinical presentation, 495-496
 - intrahepatic biliary disease, 487-488
 - laboratory tests, 497-500
 - body fluids, 497-499
 - liver biopsy, 499-500
 - radiology, 499
 - medical management, 500-501
 - syndromes, 485-495
 - extrahepatic biliary disease, 486
 - hepatocellular disease, 488-495
 - alpha₁-antitrypsin deficiency, 488
 - bacterial infection, 493
 - benign recurrent intrahepatic cholestasis, 489
 - carbohydrate metabolism disorders, 491
 - cystic fibrosis, 490
 - cytomegalovirus, 491
 - drug or toxin, 495
 - Dubin-Johnson and Rotor syndrome, 488-489
 - hepatitis B, 492-493
 - herpes, 492
 - iatrogenic disease, 493-494
 - idiopathic neonatal hepatitis, 495
 - infections, 491
 - peroxisomal disorders, 490
 - rubella, 491-492
 - syphilis, 492
 - toxoplasmosis, 492
 - trihydroxycoprostanic acidemia, 489-490
 - viral disorders, 493
- Chondrodysplasia, 804
- Chorionic villus cells, in osteogenesis imperfecta, 802-803
 - prenatal diagnosis, 762
 - See also *Chromosomal mosaicism in chorionic villus sampling*.
- Chromosomes, abnormalities, counseling for, 751-753
 - cystic hygroma, posterior nuchal, 616
 - and heart defects. See *Heart defects, congenital*.
 - mosaicism in chorionic villus sampling, 867-888
 - clinical implications, 883-884
 - counseling issues and pregnancy management, 883-884
 - fetal outcome, 884

Chromosomes (*Continued*)

- etiology of, 874-882
 - chimerism and deceased co-twin, 881-882
 - confined placental mosaicism, 874-877
 - maternal cell contamination, 880-881
 - pseudomosaicism, 877-880
 - pregnancy loss, 735-736
- Circulation in normal fetus, 923-926
- Citrullinemia, 768
- Cloning, NF1 and NF2 genes, 837
- Co-twin, deceased, 881-882
- Cocaine, and fetal anomalies, 563
- Cognition, hyperbilirubinemia effects, 332-339
 - processing systems of brain. *See Plasticity, in sensory and cognitive processing systems.*
- Collagen defects in connective tissue diseases, 793-809
 - biochemical screening, molecular genetics, and inheritance
 - of collagen disorders, 800-801
 - other collagen types, 801-802
 - type II collagen disorders, 802
 - prenatal diagnosis, 802-804
 - chondrodysplasias, 804
 - Ehlers-Danlos syndrome, 804
 - osteogenesis imperfecta, 802-803
 - screening for type I and type III collagen defects, 795-800
 - Ehlers-Danlos syndrome, 798-800
 - osteogenesis imperfecta, 796-798
- Colon cancer, genetics of, 897-900
 - clinical approach and genetic counseling, 899-900
 - genetics, 898
 - molecular markers, 898-899
- Confounding and effect modification, in hyperbilirubinemia, 348-351
- Congenital malformations, 513-742
 - abdominal abnormalities, 675-702
 - abdominal and gastrointestinal defects, 680-682
 - abdominal wall defects, 682-687
 - diaphragmatic hernias, 687-688
 - duodenal atresia, 688-689
 - embryology, 676-677
 - intestinal atresias and stenosis, 689-690
 - normal ultrasound, 677-680
 - renal malformations, 690-698
 - of central nervous system, 569-595
 - amnion rupture, 573-575
 - Arnold-Chiari malformation, 585-586
 - atelencephaly/aprosencephaly, 576-577
 - corpus callosum agenesis, 573
 - craniosynostosis, 570-571
 - Dandy-Walker malformation, 586-588
 - deformation, 569-570
 - encephalocele, 581-583
 - gyral abnormalities, 571-572
 - heterotopias, 572
 - holoprosencephaly, 583-584
 - hydrocephalus, 584
 - neural tube defects, 578-581
 - porencephaly and related defects, 575-576
- heart defects, 641-673
 - chromosomal abnormality syndromes, 644-650
 - environmental factor syndromes, 657-660
 - etiologic heterogeneity syndromes, 662-663
 - gene defects, 650-657
 - unknown genesis syndromes, 660-662
- posterior nuchal cystic hygroma, 611-640
 - diagnosis, 620-622
 - embryology, 613
 - etiology, 615-619
 - incidence, 613-615
 - investigation, 625-626
 - management, 626-627
 - natural history, 622-624
 - pathogenesis, 620
 - pathology and histology, 613
 - prognosis, 625
 - recurrence risk, 627
 - syndromes, 627-634
- pregnancy loss, 723-742
 - causes of, 726-732
 - evaluation, 725-726
 - fetal loss program, 724-725
 - protocol, 732-739
- prenatal detection of structural defects, 513-546
 - deformations, 537-541
 - developmental morphology, 516-517
 - diagnosis of malformation syndromes, 517-518
 - disruptions, 541-544
 - fetal evaluation, 515-516
 - genetic etiology of malformations, 520-532
 - guidelines for ultrasound, 513-515
 - management, 519-520
 - postnatal diagnosis, 532-537
- skeletal dysplasias, 703-722
 - fetal evaluation, 704-710
 - postnatal management, 713-719
 - evaluation, 704-710
 - postnatal management, 713-719
 - prenatal radiography, 710-712
 - ultrasound evaluation, 703-704
- teratogenically-induced, 547-567
 - animal and patient studies, 549-551
 - counseling, 551
 - human teratogens, 551-563
 - principles of teratology, 547-549

- ultrasound imaging of cranium and spine, 597-609
 - anecephaly and microcephaly, 600-601
 - cerebellar development, 606
 - encephalocele, 601
 - normal fetal anatomy, 598-600
 - spinal dysraphism, 606
 - ventricular enlargement, 602-606
- Connective tissue diseases. *See Collagen defects in connective tissue diseases.*
- Consanguinity, counseling for, 753
- Corpus callosum agenesis, 573
- Costs, of early intervention, 62-63
- Counseling, pregnancy loss, 738-739
 - for sickle cell disease, 814-815
 - teratogenically-induced fetal anomalies, 551
 - for thalassemia, alpha-, 817-818
 - beta, 821
- See also Genetic counseling.*
- Cowchock syndrome, 628
- Craniosynostosis, 570-571
- Cranium, skeletal dysplasia, 706-708
 - See also Ultrasonography.*
- Cri-du-chat syndrome, heart defects, 646
- Cry analysis, in hyperbilirubinemia, 298-301
- Cumming syndrome, 628
- Cyclic nucleotides, and heme oxygenase, 282
- Cystic disorders, renal, 693
- Cystic fibrosis, and cholestasis, 490
 - prenatal diagnosis of, 799-791
 - current state of diagnosis, 787-789
 - carrier screening, 788-789
 - fertility in affected individuals, 780-781
 - future study, 789
 - gene identification, 786-787
 - direct molecular analysis, 786-787
 - occurrence risks, 780
 - prenatal detection methods, 782-785
 - DNA linkage analysis, 783-784
 - linkage disequilibrium, 784-785
 - meconium ileus, 782-783
 - microvillar intestinal enzyme analysis, 782
- Cystic hygroma, posterior nuchal, 611-640
 - anatomy, 611-613
 - diagnosis, 620-622
 - embryology, 613
 - etiology, 615-619
 - chromosomal, 616
 - recurrent isolated, 619
 - syndrome associations, 616-619
 - teratogenic, 619
 - incidence, 613-615
 - antenatal diagnosis, 614-615
 - fetal-neonatal autopsies, 615
 - miscarriage, 615
 - investigation, 625-626
 - management, 626-627
 - natural history, 622-624
 - pathogenesis, 620
 - pathology and histology, 613
 - prognosis, 625
 - recurrence risk, 627
 - syndromes, 627-634
 - Cowchock syndrome, 628
 - Cumming syndrome, 628
 - fetal alcohol syndrome, 633
 - fetal aminopterin syndrome, 634
 - fetal trimethadione exposure, 634
 - lethal multiple pterygium syndromes, 630-632
 - Noonan syndrome, 628-630
 - Robert syndrome, 632-633
 - teratogenic syndromes, 633-634
 - Turner syndrome, 627-628
- Cytochrome c oxidase deficiency, 769
- Cytomegalovirus, and cholestasis, 491
- Dandy-Walker malformation, 586-588
- Debrancher disease, 771
- Deformations, CNS abnormalities, 569-570
 - prenatal diagnosis of structural defects, 537-541
- De Lange's syndrome, 661
- Development, of heme oxygenase, 283-284
 - of infants, early intervention, 47-55, 57-65
 - relevance of stimulation, 173-178
 - and plasticity of primate cerebral cortex, 83-102
- Diabetes mellitus, 900-906
 - genetic counseling, 904-906
 - genetics, of type 1, 901-903
 - of type 2, 903-904
 - maternal, 553, 657-658
- Diagnosis, prenatal methods, 761-763
- Diaphragmatic hernias, 687-688
- Diazo reaction, bilirubin measurement, 399-401
- Diethylstilbesterol, and fetal anomalies, 559
- DiGeorge anomaly, heart defects, 662
- Disruptions, prenatal diagnosis of structural defects, 541-544
- DNA, complementary, probes in muscular dystrophies, 849
 - linkage analysis, in cystic fibrosis, 783-784
 - polymorphisms, in neurofibromatosis, 835-836
- Doppler echocardiography, 917-918
 - color, 918-919
- Down syndrome, heart defects, 648-649
 - mother-infant interaction, 26
- Dubin-Johnson syndrome, 488-489

- Duchenne muscular dystrophy. See *Muscular dystrophies, Duchenne and Becker*.
- Duodenal atresia, 688-689
- Duplication syndromes, chromosomal. See *Heart defects, congenital*.
- Dysmorphology, fetal, 758
- Dysraphism, spinal, 606
- Dystrophin, in muscular dystrophies, 846-858
 direct gene testing, 846-850
 genetic linkage analysis in at-risk relative, 849-850
 prenatal diagnosis using cDNA probes, 849
 in prenatal diagnosis, 857-858
 protein assay, 850-854
- Echocardiography, fetal, 911-937
 examination, 920-930
 cardiovascular function and fetal well being, 929
 evaluators, 922
 fetal cardiac rhythm, 927-929
 normal fetal circulation and anatomy, 923-926
 orientation, 922-923
 potential benefits, 929-930
 mother/family referral, 912-915
 ultrasound imaging, 915-920
 color Doppler, 918-919
 Doppler, 917-918
 M-mode, 917
 safety and bioeffects of, 919-920
 technology, 916-917
 two-dimensional, 917
- Ehlers-Danlos syndrome, prenatal diagnosis, 804
 screening for, 798-800
- Electrophysiology of brain function, 59
- Ellis-van Creveld syndrome, 654
- Embryology, abdominal abnormalities, 676-677
 cystic hygroma, posterior nuchal, 613
 of posterior urethral valves, 221
- Encephalocele, 581-583
 ultrasound imaging, 601
- Energy metabolism, and bilirubin neurotoxicity, 308-309
 NMR measurement of, 319-320
- Environmental factor syndromes, heart defects, 657-660
- Epidemiology, of sickle cell disease, 813
 of thalassemia, alpha-, 815
 beta, 819
- Epinephrine, and heme oxygenase, 282
- Extrapyramidal disturbance, in bilirubin encephalopathy, 374
- Facioauriculovertebral spectrum, 663
- Fanconi's syndrome, heart defects, 656
- Fatty acid metabolism, inborn errors of, 766-767
- Feet, skeletal dysplasia, 709
- Femoral hypoplasia-unusual facies syndrome, 661-662
- Fertility, and cystic fibrosis, 780-781
- Fetal alcohol syndrome, and cystic hygroma, posterior nuchal, 633
 heart defects, 658
- Fetal aminopterin syndrome, 634
- Fetal clinical genetics, 749-937
 chromosomal mosaicism in chorionic villus sampling, 867-888
 clinical implications of, 883-884
 etiology of, 874-882
 biochemical screening, molecular genetics, and inheritance of collagen disorders, 800-801
 other collagen types, 801-802
 collagen defects in connective tissue diseases, 793-809
 prenatal diagnosis, 802-804
 type I and type III collagen defects, 795-800
- cystic fibrosis, 779-791
 current state of prenatal diagnosis, 787-759
 future study, 789
 gene localization, 786-787
 prenatal detection methods, 782-785
- echocardiography, fetal, 911-937
 examination, 920-930
 mother/family referral, 912-915
 ultrasound imaging, 915-920
- genetics of adult diseases, 889-910
 atherosclerosis, 891-897
 colon cancer, 897-900
 diabetes mellitus, 900-906
 hemoglobinopathies, 811-828
 alpha-thalassemia, 815-818
 beta-thalassemia, 818-821
 future development, 821
 prenatal diagnosis, pitfalls of, 821
 sickle cell disease, 812-815
- muscular dystrophies, Duchenne and Becker, 845-865
 clinical work-up, 846
 dystrophin, gene testing, 846-850
 in prenatal diagnosis, 857-858
 protein assay, 850-854
 heterozygote (carrier) detection, 854-857
 neonatal screening and treatment, 858-860
- neurofibromatoses, 829-844
 clinical diagnosis, 831-833
 cloning of NF1 and NF2 genes, 837

- DNA polymorphisms, restriction fragment length polymorphism, and Southern blotting, 835-836
 genetic counseling, 841-843
 linkage analysis, 833-835
 molecular prenatal diagnosis, 837-841
 prenatal diagnosis, of metabolic disease, 761-777
 diagnosable disorders, 763-772
 diagnostic methods, 761-763
 prenatal treatment, 773
 prenatal genetic counseling, 749-759
 counseling issues, 751-757
 fetal dysmorphism, 758
 patient preparation for genetic termination, 757-758
 role of genetic counselor, 750-751
 Fetal loss program. *See Pregnancy loss.*
 Fetus, abdominal abnormalities. *See Abdominal abnormalities, congenital.*
 diagnosis of structural defects, 515-516
 malformation syndromes, 517-520
 teratogenically-induced anomalies. *See Teratogenically-induced fetal anomalies.*
 ultrasonic anatomy of head and spine, 598-600
- Galactosemia, 490-491, 770-771
 Gastrointestinal congenital defects, 680-682
 Gastroschisis, 685-687
 Gaze abnormalities, in bilirubin encephalopathy, 375
 Gene defect syndromes, of heart. *See Heart defects, congenital.*
 Gene, of cystic fibrosis, 786-787
 direct molecular analysis, 786-787
 of heme oxygenase, 279-280
 NF1 and NF2, cloning of, 837
 Genetic counseling, for atherosclerosis, 896-897
 chromosomal mosaicism in chorionic villus sampling, 883-884
 for colon cancer, 899-900
 for diabetes mellitus, 904-906
 for neurofibromatosis, 841-843
 prenatal. *See Prenatal genetic counseling.*
 Genetics of adult diseases. *See Adult diseases, genetics of.*
 Glucagon, and heme oxygenase, 282
 Glucose-6-phosphatase deficiency, 771
 Glutaric aciduria, type I, 763-765
 Glycogen storage diseases, 771
 Guidelines for prenatal ultrasonography, 513-515
 Gyral abnormalities, 571-572
- Head, normal fetal anatomy, 598-600
 Hearing, in bilirubin encephalopathy, 374, 377
 hyperbilirubinemia effects, 345-348
 Heart, autopsy findings in hyperbilirubinemia, 383
 Heart defects, congenital, 641-673
 chromosomal abnormality syndromes, 664-650
 deletion 10qter syndrome, 647
 deletion 18qter syndrome, 648
 deletion 4pter syndrome, 646
 deletion 4qter syndrome, 646
 deletion 5pter (cri du chat) syndrome, 646
 deletion 9pter syndrome, 647
 Down syndrome, 648-649
 duplication 3q2 (with or without deletion 3p) syndrome, 646
 Miller-Dieker syndrome (deletion 17p13.3), 647
 monosomy and trisomy syndromes, 646-650
 partial trisomy 22 syndrome, 649
 penta X syndrome, 650
 triploidy, 650
 trisomy 13 syndrome, 647
 trisomy 18 syndrome, 647-648
 trisomy 9 syndrome, 646-647
 trisomy or tetrasomy 22p (cat-eye) syndrome, 649-650
 Turner syndrome, 650
 environmental factor syndromes, 657-660
 fetal alcohol syndrome, 658
 fetal hydantoin syndrome, 658-659
 fetal valproate syndrome, 659
 infant of diabetic mother, 657-658
 maternal phenylketonuria fetal effects, 658
 retinoic acid embryopathy, 659-660
 rubella embryopathy, 657
 thalidomide embryopathy, 659
 etiologic heterogeneity syndromes, 662-663
 CHARGE association, 663
 DiGeorge anomaly, 662
 facioauriculovertebral spectrum, 663
 VACTERL association, 662-663
 gene defect syndromes, 650-657
 autosomal dominant inheritance, 651-654
 Alagille syndrome, 654
 Apert syndrome, 654
 Holt-Oram syndrome, 652-654
 Leopard syndrome and related disorders, 652
 Noonan's syndrome and related disorders, 651-652
 Shprintzen syndrome, 654
 Townes syndrome, 654
- Hands, skeletal dysplasia, 709

Heart defects (*Continued*)

- autosomal recessive inheritance, 654-657
 - Aase syndrome, 656
 - Baller-Gerold syndrome, 657
 - Bardet-Biedl syndrome, 656
 - Carpenter's syndrome, 656-657
 - Ellis-van Creveld syndrome, 654
 - Fanconi's syndrome, 656
 - McKusick-Kaufman syndrome, 656
 - Meckel-Gruber syndrome, 657
 - short-rib +/- polydactyly syndromes, 655-656
 - thrombocytopenia-absent radius syndrome, 656
- unknown genesis syndromes, 660-662
 - Beckwith-Wiedemann syndrome, 661
 - CHILD syndrome, 661
 - De Lange's syndrome, 661
 - femoral hypoplasia-unusual facies syndrome, 661-662
 - Pallister-Hall syndrome, 662
 - Rubinstein-Taybi syndrome, 661
 - Williams syndrome, 660
- Heme, and bilirubin metabolism, 359-361
- Heme oxygenase, developmental biology of, 275-291
 - characterization, 276-281
 - gene and protein organization, 279-280
 - induction of, 280
 - physiologic and biochemical properties, 278-279
 - reaction mechanism, 276-277
 - substrate specificity, 277-278
 - developmental changes, 283-284
 - hormonal effects, 281-283
 - cyclic nucleotides, 282
 - epinephrine, 282
 - glucagon, 282
 - human chorionic gonadotropin, 283
 - insulin, 282
 - steroids, 282
 - thyroxine, 281-282
 - metalloporphyrin effects, 284-286
 - tin complexes, 284-286
 - zinc complexes, 286
 - inhibitors, and bilirubin, 261-264
- Hemoglobinopathies, prenatal diagnosis of, 811-828
 - alpha-thalassemia, 815-818
 - beta-thalassemia, 818-821
 - future development, 821
 - prenatal diagnosis, pitfalls of, 821
 - sickle cell disease, 812-815
- Hemorrhage, intraventricular, and behavior in premature infants, 114-118
- Hepatitis, B, and cholestasis, 492-493
- idiopathic neonatal, 495
- Hepatocellular disease. *See Cholestatic jaundice in newborn.*
- Hernias, diaphragmatic, 687-688
- Herpes, and cholestasis, 492
- Heterotopias, 572
- Heterozygote (carrier) detection, in muscular dystrophies, 854-857
- Histology, of cystic hygroma, posterior nuchal, 613
- Holocarboxylase synthetase deficiency, 771-772
- Holoprosencephaly, 583-584
- Holt-Oram syndrome, heart defects, 652-654
- Home visits, in Mother-Infant Transaction Program, 37-40
- Hospitalization, ideal social and environmental stimulation, 198-203
 - cause and effect, 202
 - coordinated multisensory events, 201
 - infant's cues, 200-201
 - number of caregivers, 198-199
 - personal space, 202-203
 - play materials, 203
 - predictability, 201
 - rhythmicity, 199-200
 - variety, 202
- lengthy or repeated, in infancy, 197-205
 - stimulation programs, 203-205
 - handling of preterm infants, 103-112
- HPLC, laboratory measurement of bilirubin, 401-403
- Human chorionic gonadotropin, and heme oxygenase, 283
- Hydantoin syndrome, 658-659
- Hydrocephalus, 584
- 3-Hydroxy-3-methylglutaric aciduria, 766
- Hyperbilirubinemia, and brain bilirubin, 450
 - and chronic bilirubin encephalopathy, 374-377
- heme oxygenase, developmental biology of, 275-291
 - developmental changes, 283-284
 - metalloporphyrin effects, 284-286
- See also Jaundice, neonatal.*
- Hyperthermia, maternal, 554
- Immunizations, teratogenically-induced fetal anomalies, 552-553
- Inborn errors. *See Metabolic disease, prenatal diagnosis.*
- Incidence, cystic hygroma, posterior nuchal, 613-615
- Infant stimulation, 1-245
 - early intervention, why, how, and cost of, 47-55
 - lengthy or repeated hospitalization, 197-206

- ideal social and environmental stimulation, 198-203
- stimulation programs, 203-205
- mother-infant transaction program, 31-45
 - aims of intervention, 32-33
 - hypothesized outcomes, 43
 - methodology, 40-42
 - rationale of program, 31-32
 - schedule of intervention, 33-40
- parental, of high-risk infants, 11-29
 - Down's syndrome, 26
 - intervention strategies, 26-29
 - low-income, low-birthweight infants, 22-26
 - mentally retarded infants, 20-21
 - normal middle-income families, 14-20
 - observational system and data, 12-14
- plasticity, brain damage, 69-74
 - mental and behavioral effects, 70-73
 - prevention of brain damage, 67-69
 - reduction of brain damage, 69-70
- and development of primate cerebral cortex, 83-101
- corticocortical connectivity, 91-99
 - in mature monkeys, 84-91
- in sensory and cognitive systems, 57-66
- auditory development, ABR index, 59-60
- cognitive development, P300 index, 61-62
- differential functional plasticity of developing brain, 62-63
- electrophysiology of brain function, 59
- triggering experiences, brain structure and function, 77-82
- preterm infants, behavior in newborn period, 125-154
 - behavioral organization, 139-149
 - birth demographics and physiological variables, 132-134
 - clinical variables, 132
 - methods, 126-132
 - physiologic factors, 138-139
 - PREMIE organization, 132
 - PREMIE TOTAL-I, 134-137
 - PREMIE TOTAL-II, 137
- behavior and psychophysiological assessment, 155-172
- behavioral responsiveness, 113-123
 - prematurity effects, 119-122
- handling in hospitals, 103-112
- bradycardia, 106-109
- methods, 105-106
- and intraventricular hemorrhage, 114-118
- stress, in newborns in intensive care unit, 1-9
 - responses to anesthesia and surgery, 207-214
- anesthesia effects, 212
- cardiac surgery in term neonates, 210-211
- fetal stress responses, 208
- noncardiac surgery, in preterm neonates, 209-210
 - in term neonates, 208-209
- surgical stress in neonates, 211
- theory and research issues, 173-184, 185-195
 - behavioral organization of infant, 190-192
 - developmental relevance of stimulation, 173-180
 - early stimulation of high-risk infant, 193-194
 - implications of controversy, 182-183
 - individual differences in responsiveness, 180-182
 - structural-behavioral analysis, 188-190
- Infants, low-birthweight, parental stimulation, 22-26, 31-45
- Infections, and cholestasis, 491, 493-494
- pregnancy loss, 728-730
- teratogens, 551-553
- immunizations, 552-553
- rubella, 552
- syphilis, 552
- TORCH agents, 551-552
- varicella, 552
- Infertility, chromosome abnormalities, 752
- Insulin, and heme oxygenase, 282
- Intellectual deficits, in bilirubin encephalopathy, 375
- Intensive care unit, stress in neonatal infants, 1-9
- Intestine, atresias and stenosis, 689-690
- Isomerization of bilirubin, configurational, 471-473
 - structural, 473-475
- Isovaleric acidemia, 765
- Jaundice, neonatal, 245-507
 - autopsy findings, 381-396
 - central nervous system, 385-386
 - gross findings, 390
 - kernicterus history, 386-390
 - late changes, 391-393
 - microscopic findings, 391
 - systemic, 382-385
 - bilirubin, neurotoxicity of, 437-447
 - low-bilirubin kernicterus, 442-445
 - toxicity to cells, 439-442
 - role of, 359-369
 - antioxidants and heat-shock proteins, 361-362
 - as physiologic antioxidant, 362-364

Jaundice (*Continued*)

- heme and bilirubin metabolism, 359-361
- bilirubin encephalopathy, 371-379
 - bilirubin staining, 372
 - clinical features, 373-374
 - after hyperbilirubinemia, 374-377
 - neuronal injury, 373
 - neuropathology, 371-372
- brain, bilirubin, 449-465
 - blood-brain barrier, 453-454
 - and brain blood flow, 455
 - cellular binding, 456-459
 - chemistry of bilirubin, 451-452
 - entrance mechanisms, 459-461
 - hyperbilirubinemia and brain bilirubin, 450
 - non-albumin-bound bilirubin, 452-453
 - regional localization of, 455-456
- damage in healthy full-term infants, 331-358
 - discussion, 348-354
 - limitations, implications, and conclusions, 254-256
 - methods, 331-332
 - results, 332-348
- cholestasis, 483-506
 - clinical presentation, 495-496
 - laboratory tests, 497-500
 - medical management, 500-501
 - syndromes, 485-495
- heme oxygenase, developmental biology of, 275-291
 - characterization of, 276-281
 - hormonal effects, 281-283
- kernicterus assessment, 307-329
 - bilirubin neurotoxicity, 308-309
 - chemical shift and identification, 313-315
 - energy metabolism, 309-310
 - measurement of, 318-320
 - metal ion binding and pH, 316-318
 - nuclear magnetic resonance, 310-313
 - bilirubin analysis, 320-326
 - future direction, 326
 - quantitation, 315-316
 - sensitivity and resolution, 316
- laboratory measurement of bilirubin, 397-416
 - in amniotic fluid, 410-412
 - bilirubin metabolism, 397-399
 - clinical interpretation, 407-410
 - serum methods, 399-406
 - specimen requirements, 406-407
 - in urine, 412-414
- light treatment, 467-481
 - bilirubin structure, 468-470
 - color of light, 476-477
 - excretion of photoproducts, 475-476
 - photochemistry of bilirubin, 470-475

- phototherapy improvements, 477-478
- noninvasive measurement of bilirubin, 417-435
 - measurement devices, 418-420
 - research tool, 432-433
 - screening tests, 427-432
 - transcutaneous bilirubinometry, 420-427
- pharmacologic approaches, 245-273
 - bilirubin disposition in newborn, 250-252
 - enterohepatic circulation of bilirubin, 260-261
 - heme oxidase inhibitors, 261-264
 - overview, 249-250
 - phenobarbital treatment, 252-260
 - rationale for and limitations of, 245-249
- risk assessment, 293-306
 - brainstem audiometric-evoked response, 294-298
- Brazelton neonatal behavioral assessment scale, 301-303
- cry analysis, 298-301
- historical perspective, 293-294

Kernicterus, 307-329

- and acute bilirubin encephalopathy, 373-374
- autopsy findings, 386-390
- bilirubin neurotoxicity, 308-309, 442-445
 - energy metabolism, 308-309
 - in vivo disturbance, 309-310
 - neurotransmission disturbance, 308
- metal ion binding and pH, 316-318
- nuclear magnetic resonance, 310-313
 - bilirubin study, 320-326
 - chemical shift and identification, 313-315
 - energy metabolism measurement, 318-320
 - future directions, 326
 - history, 310-311
 - quantitation, 315-316
 - sensitivity and resolution, 316
 - theory, 311-313
- Kidney, autopsy findings in hyperbilirubinemia, 383
- congenital defects, 690-698
 - agenesis, 690-693
 - cystic disorders, 693
 - osathanondh, and Potter type I (infantile polycystic disease), 693
 - and Potter type II (multicystic dysplasia), 694-695
 - and Potter type III (adult polycystic disease), 696
 - and Potter type IV, 696

- posterior urethral valve and prune belly syndrome, 697-698
- Laboratory measurement of bilirubin, 397-416
- in amniotic fluid, 410-412
 - bilirubin oxidase, 405-406
 - binding measurements, 406
 - in cholestatic jaundice, 497-500
 - clinical interpretation of serum levels, 407-410
 - dialysis methods, 399-401
 - direct spectrophotometry, 401
 - HPLC, 401-403
 - metabolism, 397-399
 - reflectance spectrophotometry, 403-405
 - specimen requirements, 406-407
 - in urine, 412-414
- Lactic acidosis, inborn errors causing, 769-770
- Leopard syndrome, heart defects, 652
- Lethal multiple pterygium syndrome, 630-632
- Light treatment for neonatal jaundice, 467-481
- bilirubin structure, 468-470
 - color of light, 476-477
 - excretion of photoproducts, 475-476
 - photochemistry of bilirubin, 470-475
 - configurational isomerization, 471-473
 - improvements, 477-478
 - photo-oxidation, 470
 - structural isomerization, 473-475
- Linkage analysis, disequilibrium, in cystic fibrosis, 784-785
- in Duchenne muscular dystrophy, of at-risk relatives, 849-850
 - in neurofibromatosis, 833-835
- Lipids, and atherosclerosis, 892-893
- Lithium, and fetal anomalies, 559
- Liver, autopsy findings in hyperbilirubinaemia, 382-383
- biopsy in cholestatic jaundice, 499-500
- Lung, autopsy findings in hyperbilirubinaemia, 383-385
- Lysosomal storage diseases, 772
- M-Mode echocardiography, 917
- Malformation syndromes, diagnosis, 517-518
- genetic etiology, 520-532
 - management, 519-520
 - postnatal diagnosis, 532-537
- Maple syrup urine disease, 767
- Maternal, cell contamination, in chorionic villus sampling, 880-881
- diabetes mellitus, 553, 657-658
- hyperthermia, 554
- phenobarbital treatment for neonatal jaundice, 252-254
- phenylketonuria, 553-554, 658
- See also *Mother-infant interaction*.
- McKusick-Kaufman syndrome, 656
- Meckel-Gruber syndrome, 657
- Meconium ileus, in cystic fibrosis, 782-783
- Menke disease, 772
- Metabolic disease, prenatal diagnosis, 761-777
- diagnostic methods, 761-763
 - amniocentesis, 762
 - chorionic villus sampling, 762
 - fetal tissue biopsy, 763
 - investigational methods, 763
 - percutaneous umbilical blood sampling, 762
- inborn errors, of amino acid metabolism, 767-768
- maple sugar urine disease, 767
 - phenylketonuria, 767
 - tyrosinemia, 767-768
- of branched chain organic acids, 766
- 3-hydroxy-3-methylglutaric aciduria, 766
 - beta-ketothiolase deficiency, 766
- of carbohydrate metabolism, 770-771
- galactosemia, 770-771
- of fatty acid metabolism, 766-767
- long chain acyl-CoA dehydrogenase deficiency, 766-767
 - medium chain acyl-CoA dehydrogenase deficiency, 766
- glycogen storage disease, 771
- glycogen storage disease, type III (Debrancher disease), 771
 - alpha-1,4-glucosidase deficiency (Pompe disease), 771
 - glucose-6-phosphatase deficiency (Von Gierke disease), 771
- and lactic acidosis, 769-770
- cerebrohepatorenal syndrome of Zellweger, 769
- cytochrome c oxidase deficiency, 769
- multiple acyl-CoA dehydrogenase deficiency, 769-770
- pyruvate carboxylase deficiency, 770
- pyruvate dehydrogenase deficiency, 770
- lysosomal storage diseases, 772
- mucopolidosis, type II, 772
- of organic acids, 763-765
- glutaric aciduria, type I, 763-765
 - isovaleric acidemia, 765
 - methylmalonic acidemia, 765
 - propionic acidemia, 765
- trace metal and vitamin metabolism, 771-772

- Metabolic disease (*Continued*)
 holocarboxylase synthetase deficiency, 771-772
 urea cycle disorders, 768-769
 argininosuccinic aciduria, 768-769
 citrullinemia, 768
 ornithine-transcarbamylase deficiency, 768
 prenatal treatment of, 773
 Metabolic errors, in pregnancy loss, 737
 Metalloporphyrins, and heme oxygenase, 284-286
 Metals, trace, inborn errors of, 771-772
 Methotrexate, and fetal anomalies, 556
 Methyl mercury, and fetal anomalies, 559-560
 Methylmalonic acidemia, 765
 Microbiology, pregnancy loss, 736
 Microcephaly, ultrasound imaging, 600-601
 Microvillar intestinal enzyme analysis, for cystic fibrosis, 782
 Miller-Dieker syndrome, 647
 Miscarriage, cystic hygroma incidence, 615
 Molecular genetics, collagen defects in connective tissue diseases, 800-801
 of sickle cell disease, 812-813
 of thalassemia, alpha-, 815
 beta-, 818-819
 Molecular markers for colon cancer, 898-899
 Morphogenesis errors, 730
 Mosaicism, chromosomal. *See Chromosomal mosaicism in chorionic villus sampling.*
 Mother-infant interaction, transaction program, 31-45
 aims of intervention, 32-33
 Down's syndrome, 26
 hypothesized outcomes, 43
 methodology, 40-42
 measures, 42
 subjects, 40-42
 rationale of program, 31-32
 schedule of intervention, 33-40
 day 1: introduction, 33
 day 2: homeostasis, 33
 day 3: motor system, 34-35
 day 4: state regulation, 35
 day 5: social interaction, 35-37
 home visits, 37-40
 Mucopolipidosis, type II, 772
 Multifactorial disorders, counseling for, 755-756
 Muscular dystrophies, Duchenne and Becker, 845-865
 clinical workup, 846
 dystrophin, direct gene testing, 846-850
 protein assay, 850-854
 in fetus or abortus, 857-858
 in prenatal diagnosis, 857-858
 heterozygote (carrier) detection, 854-857
 neonatal screening and treatment, 858-860
 Myelomeningocele, 580-581
 Neck. *See Cystic hygroma, posterior nuchal.*
 Neonatal infants, anesthesia effects, 212
 cardiac surgery, 210-211
 graded surgical stress, 211
 hyperbilirubinemia. *See Jaundice, neonatal.*
 noncardiac surgery, 208-210
 obstructive uropathy, 215-239
 posterior urethral valves, 220-229
 ureteroceles, 229-236
 ureteropelvic junction obstruction, 215-219
 stress in intensive care unit, 1-9
 Neural tube defects, anencephaly, 578-580
 myelomeningocele, 580-581
 Neurofibromatosis, 829-844
 clinical diagnosis, 831-833
 cloning of NF1 and NF2 genes, 837
 DNA polymorphisms, restriction fragment length polymorphism, and Southern blotting, 835-836
 linkage analysis, 833-835
 prenatal diagnosis, 837-841
 Neuropathology, of bilirubin encephalopathy, 371-372
 hyperbilirubinemia effects, 339-345
 Neurotoxicity of bilirubin, 308-309, 437-447
 without hyperbilirubinemia, 375-377
 kernicterus, 442-445
 toxicity to cells, 439-442
 Noonan syndrome, cystic hygroma, posterior nuchal, 628-630
 heart defects, 651-652
 Nuclear magnetic resonance in neonatal jaundice. *See Kernicterus.*
 Omphalocele, 682-685
 Organic acids, inborn errors of, 763-765
 branched chain, 766
 Ornithine-transcarbamylase deficiency, 768
 Ospanthandh, and Potter type I (infantile polycystic disease), 693
 and Potter type II (multicystic dysplasia), 694-695
 and Potter type III (adult polycystic disease) 696
 and Potter type IV, 696
 Osteogenesis imperfecta, prenatal diagnosis, 802-804
 screening for, 796-798

- P300 index, 61-62
- Pallister-Hall syndrome, heart defects, 662
- Pancreas, autopsy findings in hyperbilirubinemia, 385
- Parents, Down's syndrome, 26
- intervention strategies, 26-29
 - low-income, low-birthweight infants, 22-26
 - mentally retarded infants, 20-21
 - normal middle-income families, 14-20
 - observational system and data, 12-14
 - stimulation of high-risk infants, 11-29
- Pathology of cystic hygroma, posterior nuchal, 613
- Penta X syndrome, 650
- Percutaneous umbilical blood sampling, 762
- Peroxisomal disorders, 490
- pH, and metal ion binding, in kernicterus, 316-318
- Pharmacologic approach to neonatal jaundice, 245-273
- bilirubin disposition, 250-252
 - bilirubin metabolism, 249-250
 - and enterohepatic circulation of bilirubin, 260-261
 - heme oxygenase inhibitors, 261-264
 - phenobarbital treatment, 252-260
 - antenatal and postnatal combination, 257
 - inducing agents and combinations, 257-258
 - maternal treatment, 252-254
 - postnatal treatment, 255-257
 - safety of, 258-260
 - rationale for and limitations of, 245-249
- Phenobarbital, in neonatal jaundice, 252-260
- antenatal and postnatal combination, 257
 - inducing agents and combinations, 257-258
 - maternal treatment, 252-254
 - postnatal treatment, 255-257
 - safety of, 258-260
- Phenylketonuria, 767
- maternal, 553-554, 658
- Photochemistry of bilirubin, 470-475
- color of light, 476-477
 - configurational isomerization, 471-473
 - excretion of photoproducts, 475-476
 - photo-oxidation, 470
 - structural isomerization, 473-475
- Photographs, pregnancy loss, 733
- Placental mosaicism, 874-877
- Plasticity, brain damage, 67-74
- mental and behavioral effects, 70-73
 - prevention of, 67-69
 - reduction of, 69-70
 - and development of primate cerebral cortex, 83-102
 - corticocortical connections in mature monkeys, 84-91
 - afferent and efferent organization, 87-91
 - methods, 84-87
 - corticocortical connectivity, 91-98
 - retrograde tracings in prefrontal cortex, 92-94
 - termination of afferents and efferents, 94-98
 - in sensory and cognitive processing systems, 57-66
 - auditory function, ABR index, 59-60
 - cognitive development, P300 index, 61-62
 - in developing brain, 62-63
 - electrophysiology of brain function, 59
 - triggering experiences, brain structure and function, 77-82
- Play materials, infants in acute care hospital units, 203
- Polymerase chain reaction technology, in muscular dystrophies, 849
- Pompe disease, 771
- Porencephaly, 575-576
- Postnatal diagnosis of malformation syndromes, 532-537
- Pregnancy loss, 723-742
- causes of, 726-732
 - amniotic band disruption sequence, 727
 - hemorrhage, 726
 - immunologic, 730-731
 - implantation of placenta, 727
 - infections, 728-730
 - intrafetal problems, 727
 - metabolic, 731-732
 - morphogenesis errors, 730
 - neoplastic, 731
 - placental compromise, 726-727
 - umbilical cord accidents, 727
 - fetal loss program, 724-725
 - protocol, 732-739
 - chromosomal studies, 735-736
 - counseling, 738-739
 - history and physical examination, 732
 - metabolic errors, 737
 - microbiologic studies, 736
 - non-immune fetal hydrops, 737
 - perinatal autopsy, 737-738
 - photographs, 733
 - radiographic studies, 733-735
- Pregnancy management, chorionic villus sampling mosaicism, 883-884
- Premature infants, bilirubin encephalopathy, 376-377
- PREMIE scores. *See Preterm infants, behavior in newborn periods.*
- Prenatal detection of structural defects, 513-546

Prenatal detection of structural defects

(Continued)

- collagen defects in connective tissue diseases, 802-804
- deformations, 537-541
- developmental morphology, 516-517
- diagnosis of fetal malformation syndromes, 517-518
- disruptions, 541-544
- dystrophin protein testing, 857-858
- fetal evaluation, 515-516
- genetic etiology of malformations, 520-532
- guidelines for ultrasound, 513-515
- hemoglobinopathies, 821
- management, 519-520
- of neurofibromatoses, 837-741
- postnatal diagnosis, 532-537
- sickle cell disease, 814
- thalassemia, alpha-, 817
- beta-, 820-821

See also *Fetal clinical genetics*.

Prenatal genetic counseling, 749-750

- counseling issues, 751-757
 - chromosome abnormalities, 751-753
 - consanguinity, 753
 - genetic screening issues, 753-755
 - multifactorial disorders, 755-756
 - ultrasonography, 756-757
- fetal dysmorphology, 758
- patient preparation for genetic termination, 757-758
- role of genetic counselor, 750-751
- Preterm infants, behavior in newborn periods, 125-154
 - clinical variables, 132
 - comparison with other studies, 147-149
 - methods, 126-132
 - motor organization, 141-142
 - orientation, 139-141
 - physiologic factors, 138-139
 - physiologic organization, 144
 - PREMIE organization, 132
 - PREMIE self-regulation items and
 - PREMIE TOTAL score, 144-146
 - PREMIE TOTAL score changes, 146
 - PREMIE TOTAL-I, 132-137
 - and birth demographics and physiologic variables, 132-134
 - multiple regression analysis, 134-137
 - PREMIE TOTAL-II, 137-138
 - and birth demographics and physiologic variables, 137
 - stepwise regression analysis, 137-138
 - handling in hospitals, 103-112
 - bradycardia, 106-107
 - physiologic changes, 107-109
 - methods, 105-106
 - stability in performance, 147
 - state organization, 142-144
 - and psychophysiological assessment, 155-172

radiography, 710-712

responsivity, 113-123

prematurity, and impact of complications, 119-122

and intraventricular hemorrhage, 114-118

Propionic acidemia, 765

Protective apathy, 125-154

Proteins, heat-shock, and antioxidants, 361-362

Prune belly syndrome, 697-698

Pseudomoaisicism, 877-880

Psychophysiology, and behavior of preterm infants, 155-172

Pterygium syndromes, lethal multiple, 630-632

Public policies for early intervention, 53-54

Pyruvate carboxylase deficiency, 770

Pyruvate dehydrogenase deficiency, 770

Radiation, and fetal anomalies, 560

Radiography, in cholestatic jaundice, 499

pregnancy loss, 733-735

prenatal, 710-712

Reaction mechanism, of heme oxygenase, 276-277

Restriction fragment length polymorphism, in neurofibromatoses, 835-836

Retinoic acid embryopathy, 659-660

Risk factors, for atherosclerosis, 892-893

cystic fibrosis, 780

in hyperbilirubinemia, 351-354

Robert syndrome (Robert-SC phocomelia syndrome), 632-633

Rotor syndrome, 488-489

Rubella, and cholestasis, 491-492

heart defects, 657

teratogenically-induced fetal anomalies, 552

Rubinstein-Taybi syndrome, 661

Screening, for cystic fibrosis carrier, 788-789

for sickle cell disease, 813-814

Sensory processing systems of brain. See *Plasticity, in sensory and cognitive processing systems*.

Short-rib +/- polydactyly syndromes, 655-656

Shprintzen syndrome, 650

Sickle cell disease, 812-815

carrier screening, 813-814

clinical aspects, 813

counseling aspects, 814-815

epidemiology, 813

molecular basis, 812-813

- prenatal diagnosis, 814
- Skeletal dysplasias, 703-722
 - fetal evaluation, 704-710
 - cranium and spine, 706-608
 - hands and feet, 709
 - long bones, 704-706
 - non-skeletal involvement, 709-710
 - thorax, 708
 - postnatal management, 713-719
 - prenatal radiography, 710-712
 - ultrasound evaluation, fetal, 703-704
- Southern blotting, in neurofibromatosis, 835-836
- Specimen requirements, bilirubin measurement, 406-407
- Spectrophotometry of bilirubin, direct, 401
- reflectance, 403-405
- Spine, skeletal dysplasia, 706-708
 - See also *Ultrasonography*.
- Statistical analysis of premature infant behavior. See *Preterm infants, behavior in newborn periods*.
- Steroids, and heme oxygenase, 282
- Stress, neonatal anesthesia and surgery, 209-216
 - anesthesia effects, 212
 - cardiac surgery in term neonates, 210-211
 - fetal responses, 208
 - graded surgery in neonates, 211
 - in intensive care unit, 1-9
 - noncardiac surgery, in preterm neonates, 209-210
 - in term neonates, 208-209
- Substrate specificity, of heme oxygenase, 277-278
- Surgery, neonatal stress responses. See *Stress*.
- Syphilis, and cholestasis, 492
 - teratogenically-induced fetal anomalies, 552
- Temporal evolution, of bilirubin encephalopathy, 374
- Teratogenically-induced fetal anomalies, 547-567
 - acquired immunodeficiency syndromes, 563
 - cocaine, 563
 - counseling, 551
 - cystic hygroma, posterior nuchal, 619
 - drugs, chemicals, and physical agents, 554-563
 - alcohol, 554-555
 - aminopterin and methotrexate, 556
 - anticonvulsants, 556-559
 - diethylstilbestrol, 559
 - lithium, 559
 - methyl mercury, 559-560
 - radiation, 560
 - tetracycline, 560
 - thalidomide, 560-561
 - vitamin A congeners, 561-562
 - warfarin, 562-563
- human teratogens, 551-563
 - infectious agents, 551-553
 - immunizations, 552-553
 - infectious agents, 551-553
 - rubella, 552
 - syphilis, 552
 - TORCH agents, 551-552
 - varicella, 552
- maternal diseases, 553-554
 - diabetes mellitus, 553
 - hyperthermia, 554
 - phenylketonuria, 553-554
- principles of, 547-549
 - developmental stages, 548
 - dose-response relationships, 549
 - genetic differences, 548-549
 - teratogenic effects, 549
- risk determination, 549-551
 - animal studies, 549-550
 - case control studies, 550
 - case reports, 550-551
 - cohort studies, 550
- Termination, genetic, 757-758
- Tetracycline, and fetal anomalies, 560
- Thalassemia, alpha, 815-818
 - carrier screening, 816-817
 - clinical aspects, 815-816
 - counseling aspects, 817-818
 - epidemiology, 816
 - molecular basis, 815
 - prenatal diagnosis, 817
- beta, 818-821
 - carrier screening, 820
 - clinical aspects, 819-820
 - counseling, 821
 - epidemiology, 819
 - molecular basis, 818-819
 - prenatal diagnosis, 820-821
- Thalidomide, and fetal anomalies, 560-561, 659
- Theory and research of infant stimulation, 173-183, 185-195
 - behavioral organization of infant, 190-192
 - developmental relevance of, 173-178
 - early stimulation of high-risk infant, 193-194
 - implications of controversy, 181
 - individual differences in responsiveness, 178-180
 - structural-behavioral analysis, 188-190
- Thorax, skeletal dysplasia, 708
- Thrombocytopenia-absent radius syndrome, 656
- Thyroxine, and heme oxygenase, 281-282

- Tin-protoporphyrin, in neonatal jaundice, 263-264
and heme oxygenase, 284-286
- TORCH agents, teratogenically-induced fetal anomalies, 551-552
- Total parenteral nutrition cholestasis, 493-494
- Townes syndrome, heart defects, 654
- Toxoplasmosis, and cholestasis, 492
- Transcutaneous bilirubinometry, 420-433
as replacement for serum bilirubin testing, 420-427
as research tool, 432-433
as screening device, 427-432
cut-point decision analysis, 432
- Trihydroxycoprostanic acidemia, 490
- Trimethadione, fetal exposure, 634
- Triploidy, heart defects, 650
- Trisomy 9 syndrome, heart defects, 646-647
- Trisomy 13 syndrome, heart defects, 647
- Trisomy 18 syndrome, heart defects, 647-648
- Trisomy 22 syndrome, partial, 649
- Trisomy or tetrasomy 22p syndrome, 649-650
- Turner syndrome, cystic hygroma, posterior nuchal, 627-628
heart defects, 650
- Tyrosinemia, 767-768
- Ultrasonography, abdominal, normal fetus, 677-680
and counseling for abnormalities, 756-757
of cranium and spine, 597-609
anencephaly and microcephaly, 600-601
cerebellar development, 606
encephalocele, 601
normal fetal anatomy, 598-600
spinal dysraphism, 606
ventricular enlargement, 602-606
cystic hygroma, posterior nuchal, 622
guidelines for prenatal evaluations, 513-515
for osteogenesis imperfecta, 803
skeletal dysplasias, fetal, 703-704
See also *Echocardiography, fetal*.
- Umbilical blood sampling, 762
- Urea cycle disorders, 768-769
- Ureteroceles, 231-238
diagnosis, 234-237
duplications, 238
management, 237-238
presentation, 234
- Ureteropelvic junction obstruction, 217-221
bilateral obstruction, 220-221
diagnosis, 218
nephrectomy, 219-220
pathogenesis, 218
preliminary urinary diversion, 221
presentation, 218
treatment, 218-219
- Urethral valves, posterior, 697-698
- Urine, bilirubin measurement, 412-414
- Uropathy, obstructive, in newborn, 215-239
posterior urethral valves, 220-229
ureteroceles, 229-236
uteropelvic junction obstruction, 215-219
- VACTERL association, heart defects, 662-663
- Valproate syndrome, fetal, 659
- Valves, posterior urethral, 220-229
anatomy, 221-223
diagnosis, 225-228
embryology, 221
management, 228-229
pathophysiology, 223
presentation, 223-225
- Variables in Mother-Infant Transaction Program, 42
antecedent, 42
intermediate, 42
outcome, 42
- Varicella-induced fetal anomalies, 552
- Ventricular enlargement, ultrasound imaging, 602-606
- Vitamin A, and fetal anomalies, 561-562
- Vitamin metabolism, inborn errors of, 771-772
- Von Gierke disease, 771
- Warfarin, and fetal anomalies, 562-563
- Williams syndrome, heart defects, 660
- Zinc-metalloporphyrin complexes, 286

